Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Cartilage degradation products as markers for evaluation of patients with rheumatic disease

Cartilage degradation products as markers for evaluation of patients with rheumatic disease http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Applied Immunology Reviews CrossRef

Cartilage degradation products as markers for evaluation of patients with rheumatic disease

Christgau, Stephan; Cloos, Paul A.C
Clinical and Applied Immunology Reviews , Volume 4 (4): 277-294 – May 1, 2004
Download PDF

Cartilage degradation products as markers for evaluation of patients with rheumatic disease

Christgau, Stephan; Cloos, Paul A.C
Clinical and Applied Immunology Reviews , Volume 4 (4): 277-294 – May 1, 2004

Loading next page...
 
/lp/crossref/cartilage-degradation-products-as-markers-for-evaluation-of-patients-1N2vEDFDQK

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
CrossRef
ISSN
1529-1049
DOI
10.1016/j.cair.2004.01.003
Publisher site
See Article on Publisher Site

Abstract

Journal

Clinical and Applied Immunology Reviews – CrossRef

Published: May 1, 2004

References

  • Markers of disease in rheumatoid arthritis
    Wollheim
  • Molecular markers for osteoarthritis: the road ahead
    DeGroot
  • Management of rheumatoid arthritis
    Stucki
  • Clinical and laboratory assessments in rheumatoid arthritis and osteoarthritis
    Scott
  • Interpreting radiographic data in rheumatoid arthritis
    Ory
  • Connective tissue markers of Rheumatoid Arthritis
    Møller
  • Isomerized aggrecan fragments are released during cartilage degradation and can be measured in serum
    Christgau
  • Cartilage degradation and oxidative damage in osteoarthritic and rheumatoid arthritic patients
    Deberg
  • Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage
    Garnero
  • Baseline levels of urinary glucosyl-galactosyl pyridinoline and type II collagen C-telopeptide are associated with progression of joint destruction in patients with early rheumatoid arthritis
    Garnero
  • Collagen type II degradation products in urine as an index of cartilage degradation
    Christgau
  • Imaging in rheumatoid arthritis–why MRI and ultrasonography can no longer be ignored
    Østergård
  • Genetic markers of osteoarticular disorders: facts and hopes
    Brandi
  • The chondrocyte
    Archer
  • Interaction of chondrocytes, extracellular matrix and growth factors: relevance for articular cartilage tissue engineering
    van der Kraan
  • Aging, articular cartilage chondrocyte senescence and osteoarthritis
    Martin
  • Collagens: Molecular biology, diseases and potential for therapy
    Prockop
  • Evidence for altered synthesis of type II collagen in patients with osteoarthritis
    Nelson
  • Uncoupling of type II collagen metabolism predicts progression of joint damage in patients with knee osteoarthritis
    Garnero
  • The collagens of articular cartilage
    Eyre
  • Concentrations of pyridinoline and deoxypyridinoline in joint tissues from patients with osteoarthritis or rheumatoid arthritis
    Takahashi
  • Levels of serum and synovial fluid pyridinium crosslinks in patients with rheumatoid arthritis
    Furumitsu
  • Elevation of a collagenase generated type II collagen neoepitope and proteoglycan epitopes in synovial fluid following induction of joint instability in the dog
    Chu
  • Aggrecan from start to finish
    Lou
  • The structure of aggrecan and its turnover in cartilage
    Hardingham
  • Chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in progressive versus non-progressive osteoarthritis
    Fawthrop
  • Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis
    Singer
  • Aggrecan degradation in osteoarthritis and rheumatoid arthritis
    Lark
  • COMP (Cartilage Oligomeric Protein) is synthesized in ligament, tendon, meniscus and articular cartilage
    Müller
  • Production of cartilage oligomeric matrix protein (COMP) by cultured human dermal and synovial fibroblasts
    Dodge
  • Expression of cartilage oligomeric matrix protein (COMP) by embryonic and adult osteoblasts
    Di Cesare
  • Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint
    Petersson
  • Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis
    Vilim
  • Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis
    Skoumal
  • Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology
    Dragomir
  • Synovial fluid biomarker levels predict articular cartilage damage following complete medial meniscectomy in the canine knee
    Carlson
  • COMP is selectively up-regulated in degenerating acinar cells in chronic pancreatitis and in chronic-pancreatitis-like lesions in pancreatic cancer
    Liao
  • Chondrex: new marker of joint disease
    Harvey
  • Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages
    Kirkpatrick
  • Metalloproteinase inhibitors and the prevention of connective tissue breakdown
    Cawston
  • Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis
    Posthumus
  • Reduction of serum matrix MMP 1 and MMP 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy
    Brennan
  • Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis
    Green
  • Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis
    Ishiguro
  • Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation
    Manicourt
  • The role of the resting zone in growth plate chondrogenesis
    Abad
  • Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis
    Verzijl
  • Non-enzymatic covalent modifications of proteins: mechanisms, physiological consequences and clinical applications
    Cloos
  • Biomarkers in osteoarthritis
    Garnero
  • Current and future applications of bone turnover markers
    Christgau
  • Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study
    Bettica
  • Mechanisms balancing skeletal synthesis and degradation
    Blair
  • Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential
    Cloos
  • Serum crosslaps for monitoring the response in individuals undergoing antiresorptive therapy
    Christgau
  • Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate
    Eastell
  • Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women
    Bruyere
  • Urinary collagen type II C-telopeptide fragments are sensitive markers of matrix metalloproteinase-dependent cartilage degradation in rat adjuvant-induced arthritis
    De Ceuninck
  • Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor
    Leff
  • In vitro model of human articular cartilage degradation
    Shingleton
  • Increased serum levels of cartilage oligomeric matrix protein in chronic erosive arthritis in rats
    Vingsbo-Lundberg
  • The assessment of inflammation, cartilage matrix, and bone loss in experimental monoarticular arthritis of the rat
    Seed
  • Longitudinal characterization of synovial fluid biomarkers in the canine meniscectomy model of osteoarthritis
    Lindhorst
  • The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis
    Harrison
  • A randomized trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects
    Hansen
  • Connective tissue metabolism in patients with active rheumatoid arthritis during treatment with prednisolone and/or DMARD
    Jensen
  • Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint
    Sharif
  • The effects of bisphosphonates on CartiLaps: a new marker for cartilage degradation
    Lehmann